TOVX (Theriva Biologics) Cyclically Adjusted PB Ratio: (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TOVX Theriva Biologics Inc TOVX
26 GF Score
Price $0.24
! 3 Warning Signs
View Full Analysis

What is Theriva Biologics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Theriva Biologics  (AMEX:TOVX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Theriva Biologics Cyclically Adjusted PB Ratio Related Terms


Theriva Biologics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Theriva Biologics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theriva Biologics Cyclically Adjusted PB Ratio Chart

Theriva Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.02 0.05 0.02 0.02

Theriva Biologics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.02 0.00 0.00

TOVX vs BIVI, BCLI, LNAI: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Theriva Biologics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theriva Biologics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theriva Biologics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Theriva Biologics's Cyclically Adjusted PB Ratio falls into.


TOVX
26GF Score
Theriva Biologics Inc TOVX
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theriva Biologics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Theriva Biologics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Theriva Biologics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.266/333.9520*333.9520
=0.266

Current CPI (Jun. 2026) = 333.9520.

Theriva Biologics Quarterly Data

Book Value per Share CPI Adj_Book
201609 -447.600 241.428 -619.137
201612 295.769 241.432 409.112
201703 197.615 243.801 270.688
201706 322.000 244.955 438.989
201709 -1,118.667 246.819 -1,513.583
201712 -99.733 246.524 -135.103
201803 -212.400 249.554 -284.233
201806 -432.467 251.989 -573.133
201809 -177.762 252.439 -235.162
201812 182.387 251.233 242.438
201903 127.288 254.202 167.222
201906 75.925 256.143 98.989
201909 1.612 256.759 2.097
201912 -43.881 256.974 -57.026
202003 -73.437 258.115 -95.014
202006 -98.800 257.797 -127.986
202009 -109.304 260.280 -140.242
202012 -61.915 260.474 -79.381
202103 150.754 264.877 190.068
202106 144.896 271.696 178.097
202109 138.890 274.310 169.088
202112 123.879 278.802 148.384
202203 107.298 287.504 124.633
202206 97.278 296.311 109.635
202209 87.405 296.808 98.343
202212 85.669 296.797 96.394
202303 79.094 301.836 87.510
202306 66.010 305.109 72.250
202309 60.337 307.789 65.466
202312 53.882 306.746 58.661
202403 45.757 312.332 48.924
202406 28.906 314.175 30.726
202409 9.413 315.301 9.970
202412 6.854 315.605 7.252
202503 5.570 319.799 5.817
202506 1.173 322.561 1.214
202509 0.654 324.800 0.672
202512 0.431 324.054 0.444
202603 0.336 330.213 0.340
202606 0.266 333.952 0.266

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Theriva Biologics Business Description

Address 9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
26GF Score

Get the complete analysis for TOVX

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24
Price